Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

    Diabetes, Obesity and Metabolism Date published:

  • Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

    Nephrology Dialysis Transplantation Date published:

  • Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:

  • Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS)

    American Journal of Respiratory and Critical Care Medicine Date published:

  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

    Arthritis & Rheumatology Date published:

  • Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

    Kidney International Reports Date published:

  • Barriers to Care: New Medications and CKD

    Kidney International Reports Date published:

  • Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

    American Journal of Kidney Diseases Date published:

  • Daprodustat and Heart Failure in CKD

    Journal of the American Society of Nephrology Date published:

  • Combination Treatment with Verinurad and Allopurinol in CKD

    Journal of the American Society of Nephrology Date published:

  • Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

    The Lancet Regional Health - Western Pacific Date published:

  • Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

    Circulation Date published:

  • Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin

    JAMA Cardiology Date published: